| Anti-PEG IgM is a major contributor to the accelerated blood clearance of polyethylene glycol-conjugated protein Y Mima, Y Hashimoto, T Shimizu, H Kiwada, T Ishida Molecular pharmaceutics 12 (7), 2429-2435, 2015 | 184 | 2015 |
| Anti-PEG IgM and complement system are required for the association of second doses of PEGylated liposomes with splenic marginal zone B cells T Shimizu, Y Mima, Y Hashimoto, M Ukawa, H Ando, H Kiwada, T Ishida Immunobiology 220 (10), 1151-1160, 2015 | 82 | 2015 |
| A hydroxyl PEG version of PEGylated liposomes and its impact on anti-PEG IgM induction and on the accelerated clearance of PEGylated liposomes T Shimizu, ASA Lila, R Fujita, M Awata, M Kawanishi, Y Hashimoto, ... European Journal of Pharmaceutics and Biopharmaceutics 127, 142-149, 2018 | 70 | 2018 |
| Tight junction modulation at the blood-brain barrier: Current and future perspectives Y Hashimoto, M Campbell Biochimica et Biophysica Acta (BBA)-Biomembranes 1862 (9), 183298, 2020 | 68 | 2020 |
| Relationship between the concentration of anti-polyethylene glycol (PEG) immunoglobulin M (IgM) and the intensity of the accelerated blood clearance (ABC) phenomenon against … Y Hashimoto, T Shimizu, ASA Lila, T Ishida, H Kiwada Biological and Pharmaceutical Bulletin 38 (3), 417-424, 2015 | 55 | 2015 |
| Claudin-5-binders enhance permeation of solutes across the blood-brain barrier in a mammalian model Y Hashimoto, K Shirakura, Y Okada, H Takeda, K Endo, M Tamura, ... Journal of Pharmacology and Experimental Therapeutics 363 (2), 275-283, 2017 | 50 | 2017 |
| Generation, characterization and in vivo biological activity of two distinct monoclonal anti-PEG IgMs Y Hashimoto, T Shimizu, Y Mima, ASA Lila, T Ishida, H Kiwada Toxicology and applied pharmacology 277 (1), 30-38, 2014 | 50 | 2014 |
| Engineered membrane protein antigens successfully induce antibodies against extracellular regions of claudin-5 Y Hashimoto, W Zhou, K Hamauchi, K Shirakura, T Doi, K Yagi, ... Scientific reports 8, 8383, 2018 | 39 | 2018 |
| Potential for tight junction protein–directed drug development using claudin binders and angubindin-1 Y Hashimoto, K Tachibana, SM Krug, J Kunisawa, M Fromm, M Kondoh International journal of molecular sciences 20 (16), 4016, 2019 | 34 | 2019 |
| Roles of the first-generation claudin binder, Clostridium perfringens enterotoxin, in the diagnosis and claudin-targeted treatment of epithelium-derived cancers Y Hashimoto, K Yagi, M Kondoh Pflügers Archiv-European Journal of Physiology 469, 45-53, 2017 | 31 | 2017 |
| A novel platform for cancer vaccines: antigen-selective delivery to splenic marginal zone B cells via repeated injections of PEGylated liposomes T Shimizu, AS Abu Lila, Y Kawaguchi, Y Shimazaki, Y Watanabe, Y Mima, ... The Journal of Immunology 201 (10), 2969-2976, 2018 | 30 | 2018 |
| The CLDN5 gene at the blood-brain barrier in health and disease Y Hashimoto, C Greene, A Munnich, M Campbell Fluids and Barriers of the CNS 20, 22, 2023 | 28 | 2023 |
| B cell-intrinsic toll-like receptor 7 is responsible for the enhanced anti-PEG IgM production following injection of siRNA-containing PEGylated lipoplex in mice Y Hashimoto, ASA Lila, T Shimizu, T Ishida, H Kiwada Journal of controlled release 184, 1-8, 2014 | 27 | 2014 |
| Claudin-5: a pharmacological target to modify the permeability of the blood–brain barrier Y Hashimoto, M Campbell, K Tachibana, Y Okada, M Kondoh Biological and Pharmaceutical Bulletin 44 (10), 1380-1390, 2021 | 26 | 2021 |
| Efficacy and safety evaluation of claudin‐4‐targeted antitumor therapy using a human and mouse cross‐reactive monoclonal antibody Y Hashimoto, Y Kawahigashi, T Hata, X Li, A Watari, M Tada, ... Pharmacology research & perspectives 4 (5), e00266, 2016 | 25 | 2016 |
| Claudin‐targeted drug development using anti‐claudin monoclonal antibodies to treat hepatitis and cancer Y Hashimoto, M Fukasawa, H Kuniyasu, K Yagi, M Kondoh Annals of the New York Academy of Sciences 1397 (1), 5-16, 2017 | 23 | 2017 |
| Activation of TLR9 by incorporated pDNA within PEG-coated lipoplex enhances anti-PEG IgM production Y Hashimoto, Y Uehara, AS Abu Lila, T Ishida, H Kiwada Gene Therapy 21 (6), 593-598, 2014 | 21 | 2014 |
| Safety and efficacy of an anti-claudin-5 monoclonal antibody to increase blood–brain barrier permeability for drug delivery to the brain in a non-human primate K Tachibana, Y Hashimoto, K Shirakura, Y Okada, R Hirayama, ... Journal of Controlled Release 336 (10), 105-111, 2021 | 19 | 2021 |
| A cell assay for detecting anti-PEG immune response against PEG-modified therapeutics T Shimizu, ASA Lila, M Awata, Y Kubo, Y Mima, Y Hashimoto, H Ando, ... Pharmaceutical research 35, 223, 2018 | 19 | 2018 |
| Gene silencing using 4′-thioDNA as an artificial template to synthesize short hairpin RNA without inducing a detectable innate immune response N Tarashima, H Ando, T Kojima, N Kinjo, Y Hashimoto, K Furukawa, ... Molecular Therapy-Nucleic Acids 5, 2016 | 19 | 2016 |
Matthew CampbellTrinity College Dublin在 tcd.ie 的电子邮件经过验证
